Discover the 7 selected startups of this second batch, which will benefit from the program during the next months
Level 1 winners
Level 2 winners
SEPTEMBER 2022 WINNERS
Discover the first 10 selected startups in digital health which will benefit from the program during the next months
Level 1 winners
An early-stage start-up building the world-first virtual clinic specialized in team-based ambulatory care. We are building an ecosystem that offers holistic and personalised care for complex patients.
Our start-up builds the world's first clinic specialized in Virtual Team-Based Care. We host independent doctors, generalists, and specialists, who team up to deliver holistic care for their patients. In achieving our mission, we aim to make the health care journey of people with complex health needs easy, coordinated and efficient, whenever interaction between different health professionals is required.
Consulto aims to transform how out-patient care is delivered. Our start-up brings this transformation by democratizing Team-based care and taking it beyond hospital walls. Through Consulto's virtual team-based care, every independent doctor can provide better care to their patient. In a world where Consulto exists, independent doctors are connected to one another with no organizational hierarchy.
Glucoplay is a game-based mobile application with signaling function that helps the children to better understand their condition due to diabetes. The game educates them to take responsibility for themselves and their health, and moreover to perform certain actions for supporting their condition in a safe state in order to live a full life without social restrictions.
The idea of Glucoplay came to the Ostrowski family after their two-year-old son was diagnosed with type 1 Diabetes. Families with chronic-diseased kids typically face all sorts of difficulties. In case with type 1 diabetes one of the challenges is the early age of the diagnosed child and therefore his ability to understand peculiarities of his diagnosis, and consciously behave in a more safe and convenient way in accordance with his condition, and to understand basic factors of potential risks and dangerous situations.
Glucoplay game’s idea is to help children with diabetes to take responsibility for themselves and their health, and moreover to perform certain actions for supporting their condition in a safe state in order to live a full life without social restrictions.
The game-based application will be connected to a CGM (continuous glucose monitoring) device, such as Dexcom, which will give an opportunity for the child to monitor his condition in the real moment of time and act accordingly.
Neuria Digital Therapeuthics
Neuria develops evidence-based, gamified, digital therapeutics interventions to improve (over)consumption behaviors and addictions by restoring healthy brain reward responses to environmental cues.
Neuria Digital Therapeuthics
Neuria is a spinoff of the Neurology Unit of the University and Hospital of Fribourg developing digital therapeutic interventions for behavioral change and neuropsychiatric remediation. Our digital therapy is a true game-changer in the field of overconsumption behaviors and addiction. This is demonstrated by our first target condition: overweight and obesity.
We have identified specific cognitive tasks whose repeated practice induces highly targeted brain plasticity in the reward brain regions, resulting in a progressive reduction in the attractiveness of target foods items (the underlying human-machine interface was patented by the founder of Neuria). One month of training with our software induces long-lasting reduction in the attractiveness of the targeted unhealthy palatable foods: eating less of them becomes easier, their consumption decreases, weight decreases, and health improves.
VitalizeDx is an innovative startup dedicated to preventative medicine operating in the longevity space. At VitalizeDx, we provide accessible actionable diagnostics for personalized welllness through 16 proprietary salivary biomarkers and bundled personalized nutriceutical programs for the areas of immunity, vitality, metabolism and strength.
VitalizeDx is an innovative startup dedicated to preventative medicine operating in the longevity space. At VitalizeDx, we provide accessible actionable diagnostics for personalized welllness through 16 proprietary salivary biomarkers and bundled personalized nutriceutical programs for the areas of immunity, vitality, metabolism and strength. Our products are delivered with real-time and interactive feedback through the AI-driven VitalizeDx app. Our business model is binary: B2C with incremental subscription plans renewable every 4 months from 69 chf/month to 149 chf/month targeting retail customers of every demographic. B2B, such as beauty clinics and precision gyms with more than 500 clients, with pay per use plan and a minimum of 2 years contract. VitalizeDx is a spinoff of SICHH and has an executive team of three female technologists with more than 40 years of cumulated experience in Biotech. With its revolutionary mission to democratizing health through preventative precision medicine based on solid science and machine-learning augmentation, VitalizeDx is a unique startup with unmatched competitive positioning.
Level 2 winners
biped is a smart shoulder-worn harness that uses self-driving technology to guide blind and partially-sighted people with 3D sounds.
270 million visually impaired people worldwide use sounds to move. Most obstacles like electric vehicles, bikes, or pedestrians are silent, yet dangerous. To prevent collisions and guide you, companies developed smart canes to avoid obstacles, smart glasses to describe the scene, smart wristbands to get GPS instructions... Biped is a smart and discrete harness, worn on the shoulders, with wide-angle cameras working like a pedestrian-level self-driving car. Biped generates intuitive 3D sounds to warn you about the position of important obstacles, vehicles, pedestrians or urban elements based on risk of collision. It also provides GPS instructions. Delivered with bone conduction headphones to leave your ears free.
DETECTRA is a game-changing digital biomarker for arthritis (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis). Thanks to image recognition and artificial intelligence, DETECTRA is able to detect and monitor inflammation and swelling in joints using a smartphone picture from the hand. This technology has a significant potential to improve arthritis monitoring and patient care. We aim to develop an app-based monitoring tool that people can regularly and easily use to monitor their disease activity.
DETECTRA is a game-changing digital biomarker for arthritis monitoring. Thanks to image recognition and machine learning, it uses smartphone pictures of hand to track minor arthritis-mediated changes in finger fold patterns to monitor disease activity. It is non-invasive, specific, reliable and easy to use on a regular basis at home, by the patient himself. It is the first arthritis biomarker of its kind using this technology, and is a patented tool. It will be implemented in a mobile app to be easily usable at home by patients.
Use-case description of DETECTRA: "At home"
- Patient has app at home
- Once a week, he takes a picture of his hand for disease monitoring
- If the score given by his app is increasing or shows irregularities, the patient is invited to visit his doctor for treatment adjustments
- The doctor will use the historical monitoring data as a baseline for treatment adaptation, with the goal to shortcut upcoming flares and improve treatment outcomes
Gossik is the digital productivity assistant that helps people with ADHD structure their day and get their things done.
Spending the last 2.5 years in the market made clear that people with ADHD are struggling as one of the most to have all their things under control and get their things done. This is why we focus on this target group for the next 2-3 years before we open up to the more general market as soon as it makes sense.
Specifically, people with ADHD often fail to a) estimate how long tasks take, b) prioritize their tasks and decide what to work on, c) plan & structure their day, and d) not forget things. To battle with these things every day is extremely stressful and discouraging.
Here we can help. We have developed a digital productivity assistant that 1) guides users through their day by assisting them in estimating the duration of tasks, planning their day, prioritizing, etc., 2) actively interacts with its users to build up a personal relationship, and 3) gets to know its users (routines, most productive time, optimal structure of day, etc.) to become a better assistant every day.
We have generated over 5,000+ installs and are also collaborating with ADHD coaches, schools, and companies for their employee benefit programs. As the focus on people with ADHD is rather recent, we are applying for the fund to adjust the product to their needs and establish ourselves in the community.
Level 3 winners
Ocumeda is a telemedicine startup that offers easy, quick and affordable access to eye care at the highest medical standards. Early detection could prevent 75% of blindness worldwide. Hence, we aim to prevent unnecessary vision loss - globally. We do this in a hybrid offline and online customer interaction in combination with AI.
With Ocumeda we work on three playing fields:
1) Medical Play: Offering patients the best access to eye care through a combination of online and offline interaction. Currently, the focus lies on medical eye screenings to detect eye diseases early on. We offer this service i) through coopration with leading opticians (e.g. Fielmann) ii) or through mobile teams in elderly homes and corporates. In this approach, assistants interact with our patients and generate the required data (medical history, eye pressure, fundus picture). These data are uploaded into our telemedical cloud and analyzed by board certified ophthalmologists, supported by best-in-class medical AI.
2) Data Play: We use the vast amount of generated & labeled medical data to build AI algorithms to i) improve the screening and detection of eye diseases and ii) decode the human eye to detect e.g. cardiovascular diseases. Parallely, we partner with researchers and pharma companies to support the development of treatment options in eye care.
3) Network play: we connect the relevant players in eye care (patients, opticians, ophthalmologist, research institutes, pharma, insurances) and steer patients flows efficiently in a triage model. Thereby, we leviate the health care system from preventable costs by keeping healthy patients out of the system and directing pre-diagnosed patients to the right point of care.
We are the swiss epigenetic company estimating the environmental and lifestyle impacts on biological age, an innovative measure of premature aging and overall health.
We developed a new blood test estimating the environment and lifestyle impacts on health and longevity with epigenetics. We currently sell a lifestyle assessment to private clinics, including epigenetic testing and support, to improve personalized programs for their patients. Our goal is to increase our customer reach, while costs decrease with volume, ultimately with a worldwide direct-to-consumer approach.
Our epigenetic profile estimates biological age, a measure associated with health and longevity, and its link to environmental and lifestyle factors. By analyzing which factors are responsible for premature aging, our product helps health professionals individualize health knowledge and personalize actions for a healthier life.
Semira Gonseth Nusslé and Sébastien Nusslé, developed their idea during a four-year postdoctoral stay at the University of California San Francisco and Berkeley, inspired by their research on the epigenetic links between cancer and lifestyle and the thriving ecosystem of the Silicon Valley. The goals of the company are to perform laboratory analyses, to commercialize medical devices and consumer goods products, and to perform medical research. As of today, 100% of shares are distributed between the two founders and their associates.